The NCI-MATCH trial: lessons for precision oncology.
Peter J O'DwyerRobert J GrayKeith T FlahertyHelen X ChenShuli LiVictoria WangLisa Meier McShaneDavid R PattonJames V TricoliP Mickey WilliamsA John IafrateJeffrey SklarEdith P MitchellNaoko TakebeDavid J SimsBrent CoffeyTony FuMark RoutbortLawrence V RubinsteinRichard F LittleCarlos L ArteagaDonna MarinucciStanley R HamiltonBarbara A ConleyLyndsay N HarrisJames H DoroshowPublished in: Nature medicine (2023)
The NCI-MATCH (Molecular Analysis for Therapy Choice) trial ( NCT02465060 ) was launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial-largely for patients with treatment-refractory, malignant solid tumors. Having completed in 2023, it remains one of the largest tumor-agnostic, precision oncology trials undertaken to date. Nearly 6,000 patients underwent screening and molecular testing, with a total of 1,593 patients (inclusive of continued accrual from standard next-generation sequencing) being assigned to one of 38 substudies. Each substudy was a phase 2 trial of a therapy matched to a genomic alteration, with a primary endpoint of objective tumor response by RECIST criteria. In this Perspective, we summarize the outcomes of the initial 27 substudies in NCI-MATCH, which met its signal-seeking objective with 7/27 positive substudies (25.9%). We discuss key aspects of the design and operational conduct of the trial, highlighting important lessons for future precision medicine studies.
Keyphrases
- end stage renal disease
- study protocol
- phase iii
- chronic kidney disease
- clinical trial
- ejection fraction
- newly diagnosed
- phase ii
- palliative care
- mental health
- prognostic factors
- type diabetes
- bone marrow
- high throughput
- tyrosine kinase
- open label
- randomized controlled trial
- replacement therapy
- decision making
- cell therapy